## Abstract Infection with the gastric bacterium __Helicobacter pylori__ (in particular infection with CagAβpositive strains) and smoking have been identified as risk factors for the development of gastric cancer. Both risk factors are typically acquired early in life and prevail over decades if no
A pilot study of Helicobacter pylori infection and risk of laryngopharyngeal cancer
β Scribed by Zhannat Z. Nurgalieva; David Y. Graham; Kristina R. Dahlstrom; Qingyi Wei; Erich M. Sturgis
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 88 KB
- Volume
- 27
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
Squamous cell carcinoma of the laryngopharynx has been linked to laryngopharyngeal reflux disease. helicobacter pylori corpus gastritis decreases gastric acid secretion and provides some protection against complications of gastroesophageal reflux, including adenocarcinoma of the distal esophagus. the aim of this study was to investigate whether h. pylori infection also protects against laryngopharyngeal carcinoma.
Methods:
This was a case-control study comparing patients with histologically confirmed, previously untreated laryngeal or pharyngeal squamous cell carcinomas with cancer-free controls selected from a pool of hospital-based cancer-free controls identified during a similar time period. each subject completed a self-administered questionnaire that elicited information on age, sex, ethnicity, and tobacco and alcohol consumption. the 120 case subjects were frequency matched to 120 control subjects on age (+/- 5 years), sex, tobacco use, and alcohol use; all subjects were non-hispanic whites. h. pylori and human papillomavirus type 16 (hpv-16) seropositivity was determined by use of an enzyme-linked immunosorbent assay.
Results:
The serologic assay was unsuccessful in one case subject and nine control subjects; therefore, 119 case subjects and 111 control subjects were included in the analysis. the proportion of subjects with anti-h. pylori immunoglobulin g was similar between the two groups (32.8% among cases vs 27.0% among controls; p = .342). although seropositivity was more common in the patients with laryngeal cancer (39.1%) than in the patients with pharyngeal cancer (28.8%), this difference was neither significant (p = .241) nor associated with a significant risk of laryngeal cancer (adjusted odds ratio, 1.53; 95% confidence interval, 0.69-3.41). h. pylori seropositivity was more common among patients who were hpv-16 seronegative (38.2% vs 22.9%, p = .081), and this was particularly true among patients with laryngeal cancer (47.1% vs 18.2%; p = .089).
Conclusions:
These results do not show that h. pylori infection either protects against or promotes laryngopharyngeal carcinoma. however, segregation analyses suggested that h. pylori may play a role in laryngeal cancers not associated with hpv-16 infection, and further study in this group is warranted.
π SIMILAR VOLUMES
## Abstract __Helicobacter pylori__ (__H. pylori__), atrophic gastritis, dietary and lifeβstyle factors have been associated with gastric cancer (GC). These factors have been evaluated in a large caseβcontrol study nested in the European Prospective Investigation into Cancer and Nutrition carried o
Overexpression of cyclooxygenase (COX)-2 has been implicated in the development of cancer. This study aimed to evaluate the relationship between genetic variants in COX-2 promoter interacting with Helicobacter pylori and the susceptibility to gastric cancer (GC). Three COX-2 polymorphisms -1290A>G (
Several prospective studies have shown a significant association between Helicobacter pylori seropositivity and the risk of gastric cancer. Only a small proportion of H. pylori-infected individuals will, however, develop gastric cancer, and it is unclear what effects other factors, such as diet, mig
## Abstract __Helicobacter pylori__ infection is associated with gastric cancer. A total of 97% of the infected subjects have elevated levels of __H. pylori__ antibodies. The antibody titers have been shown to decline rapidly (40β60% within 4β12 months) only after successful eradication therapy. We